Q1 EPS Forecast for Zevra Therapeutics Lifted by Analyst

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities research analysts at Roth Capital lifted their Q1 2025 earnings per share estimates for Zevra Therapeutics in a research note issued to investors on Sunday, February 9th. Roth Capital analyst J. Aschoff now anticipates that the company will earn ($0.27) per share for the quarter, up from their prior forecast of ($0.30). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. Roth Capital also issued estimates for Zevra Therapeutics’ Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at $0.01 EPS, Q4 2025 earnings at $0.09 EPS, FY2025 earnings at ($0.17) EPS, FY2026 earnings at $0.82 EPS, FY2027 earnings at $1.53 EPS and FY2028 earnings at $1.97 EPS.

A number of other equities research analysts also recently weighed in on the company. Canaccord Genuity Group cut their price target on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Cantor Fitzgerald raised shares of Zevra Therapeutics to a “strong-buy” rating in a report on Wednesday, January 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $21.57.

Zevra Therapeutics Stock Up 2.4 %

ZVRA stock opened at $7.72 on Wednesday. Zevra Therapeutics has a 12-month low of $4.20 and a 12-month high of $9.76. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a market cap of $412.06 million, a price-to-earnings ratio of -3.92 and a beta of 2.00. The company has a 50 day moving average of $8.26 and a two-hundred day moving average of $8.03.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same quarter in the prior year, the business posted ($0.40) earnings per share.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ZVRA. FMR LLC boosted its stake in Zevra Therapeutics by 282,687.5% during the third quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after buying an additional 2,312,384 shares in the last quarter. AIGH Capital Management LLC bought a new position in Zevra Therapeutics during the fourth quarter worth about $6,577,000. Stonepine Capital Management LLC acquired a new stake in Zevra Therapeutics during the third quarter valued at approximately $4,858,000. Vestal Point Capital LP bought a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at approximately $3,644,000. Finally, Propel Bio Management LLC acquired a new position in shares of Zevra Therapeutics in the 3rd quarter worth approximately $1,248,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.